Moderna (NASDAQ:MRNA)’s stock had its “sell” rating reissued by research analysts at SVB Leerink in a research report issued to clients and investors on Thursday, AnalystRatings.com reports.
Other equities research analysts have also issued reports about the company. The Goldman Sachs Group reiterated a “buy” rating and issued a $395.00 price objective on shares of Moderna in a research note on Friday, November 5th. Wolfe Research assumed coverage on Moderna in a report on Monday, November 8th. They set an “outperform” rating and a $304.00 price objective on the stock. Piper Sandler cut their price target on Moderna to $348.00 and set an “overweight” rating on the stock in a research note on Friday, November 5th. Deutsche Bank Aktiengesellschaft started coverage on shares of Moderna in a research report on Friday, October 22nd. They issued a “sell” rating and a $250.00 price objective for the company. Finally, TheStreet upgraded Moderna from a “c+” rating to a “b-” rating in a report on Monday, November 1st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $244.31.
Shares of MRNA stock opened at $251.36 on Thursday. The company has a market capitalization of $101.91 billion, a price-to-earnings ratio of 15.41, a P/E/G ratio of 0.34 and a beta of 1.34. Moderna has a 1-year low of $102.66 and a 1-year high of $497.49. The company has a current ratio of 1.35, a quick ratio of 1.25 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $292.81 and its 200-day simple moving average is $319.00.
Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 4th. The company reported $7.70 earnings per share for the quarter, missing analysts’ consensus estimates of $9.49 by ($1.79). The company had revenue of $4.97 billion during the quarter, compared to analyst estimates of $6.29 billion. Moderna had a return on equity of 121.61% and a net margin of 59.69%. Moderna’s quarterly revenue was up 3065.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.59) EPS. On average, sell-side analysts predict that Moderna will post 26.67 EPS for the current year.
In other Moderna news, insider Juan Andres sold 15,000 shares of the stock in a transaction that occurred on Monday, September 27th. The shares were sold at an average price of $429.38, for a total value of $6,440,700.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Stephane Bancel sold 9,000 shares of the stock in a transaction that occurred on Wednesday, December 15th. The stock was sold at an average price of $272.11, for a total transaction of $2,448,990.00. The disclosure for this sale can be found here. Insiders have sold a total of 456,250 shares of company stock worth $141,185,655 over the last 90 days. 19.40% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the company. Corbenic Partners LLC bought a new position in shares of Moderna during the 3rd quarter valued at $25,000. Evermay Wealth Management LLC bought a new stake in Moderna in the 2nd quarter worth $28,000. Girard Partners LTD. bought a new stake in Moderna in the 3rd quarter worth $29,000. Winch Advisory Services LLC grew its holdings in Moderna by 1,785.7% in the 2nd quarter. Winch Advisory Services LLC now owns 132 shares of the company’s stock worth $31,000 after acquiring an additional 125 shares during the last quarter. Finally, MV Capital Management Inc. bought a new stake in Moderna in the 3rd quarter worth $32,000. 55.10% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Company Profile
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.